Status:
COMPLETED
Ameliorating Contrast Induced Nephropathy After Coronary Angiography
Lead Sponsor:
Ain Shams University
Conditions:
Coronary Artery Disease
Nephropathy; Toxic, Drugs
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
Given the limited understanding of the impact of statin and N-acetyl cysteine use before angiography in preventing contrast-induced nephropathy (CIN), the objective of this study is to evaluate the ef...
Detailed Description
A multi armed randomized controlled clinical trial to be conducted from June 2023.According to inclusion and exclusion criteria, All patients presenting to the Cardiology department at Ain Shams Unive...
Eligibility Criteria
Inclusion
- Undergoing elective Coronary angiography who will receive coronary angiography contrast media.
- Must have at least two consecutive serum creatinine measurements (Before and after Contrast exposure)
Exclusion
- Pregnant or lactating women
- Patients with Serum creatinine conc of \>2.1 mg/Dl
- Patients undergoing emergency primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
- Prior exposure to contrast media within 7 days
- Contraindication for a high-dose statin, N-acetyl Cysteine prescription
Key Trial Info
Start Date :
December 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06139952
Start Date
December 1 2023
End Date
July 1 2024
Last Update
July 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Cardiovascular Hospital
Heliopolis, Cairo Governorate, Egypt, 11355